Actively Recruiting
Evaluating the Safety and Effectiveness of ENV-294 Compared to Placebo in Adults With Moderate-to-Severe Atopic Dermatitis A 12-Week Randomized, Double-Blind Study
Led by Enveda Therapeutics · Updated on 2026-09-25
105
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. This study aims to determine if ENV-294 impacts the severity and affected area of atopic dermatitis and to observe any medical problems participants may experience while taking the drug. Participants will be randomly assigned to receive either ENV-294 or a placebo once daily by mouth for 12 weeks. They will visit the clinic every 2 to 4 weeks for checkups and tests during this period. The study includes keeping a diary of symptoms and medication intake and concludes with a final clinic visit around week 16. During the trial, participants will undergo clinical assessments to evaluate the severity and extent of their skin condition, including scores such as vIGA and EASI. Safety monitoring involves tracking adverse events and laboratory tests. Researchers will also assess pharmacokinetics and patient-reported outcomes. The total participation spans about 16 weeks, covering treatment and follow-up visits.
CONDITIONS
Brief Title
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Research Team
C
Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here